Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)

NCT04453371 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER_GOV

Sponsor class

Stopped Our local committee has denied the approval request

Conditions

Acute Respiratory Distress Syndrome

Interventions

DRUG: Tissue plasminogen activator
DRUG: Ringer solution

Sponsor

Negovsky Reanimatology Research Institute

Collaborators

[object Object]